Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Added:
1 month ago
Video Series
Added:
1 month ago
In this Radcliffe Cardiology Masterclass, Dr Harriette Van Spall (McMaster University, Canada) sits down with cardiology legend Dr Eugene Braunwald (Harvard Medical School, TIMI Study Group) to explore his life, landmark research, and advice for the next generation of cardiovascular clinicians and scientists. This discussion was originally recorded in 2021, and we share it now in remembrance of…
View more
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Added:
8 months ago
Expert Opinion
Added:
2 months ago
Added:
1 year ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical…
View more
Added:
2 months ago
Added:
1 year ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Added:
1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,…
View more
Added:
4 months ago
AF Symposium 2026 - Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss findings from the ADVENT LTO study, evaluating long-term outcomes and atrial fibrillation progression in patients who received ablation with the FARAPULSE Pulsed Field Ablation System compared to thermal ablation.The study tracked AF progression patterns, arrhythmia recurrence rates,…
View more
Added:
1 year ago